TY - JOUR
T1 - Theophylline reduces the response to nasal challenge with antigen
AU - Naclerio, Robert M.
AU - Bartenfelder, Denise
AU - Proud, David
AU - Togias, Alkis G.
AU - Meyers, Deborah A.
AU - Kagey-Sobotka, Anne
AU - Norman, Philip S.
AU - Lichtenstein, Lawrence M.
N1 - Funding Information:
From the Department of Medicine, Division of Clinical Immunology, and Department of Otolaryngology, Johns Hopkins University School of Medicine, Baltimore, Maryland. This was supported by grants Al-07290. Al-08270. HL-32272. Al-04866. NS-22488, and AI-201 1;5 from the National Ins;itutes of Health. Bethesda. Marvland. and bv a arant from Purdue Frederick dorpo;ation: Dr. Nacl&io is recipient of Teacher Investigator Award 5-KO7-NS0081 l-03 from the National Institute of Neurological and Communicative Disorders and Stroke. Requests for reprints should be addressed to Dr. Robert M. Naclerio, O’Neill Research Laboratories, Good Samaritan Hospital, 5601 Loch Raven Boulevard, Baltimore, Maryland 21239.
PY - 1985/12/20
Y1 - 1985/12/20
N2 - A nasal challenge model of allergic rhinitis was used to determine if pretreatment with oral theophylline reduces histamine release in vivo. Ten subjects were entered into a double-blind, cross-over trial. The results showed that both the physiologic response (sneezing) (p = 0.02) and the amount of mediators (histamine, kinins, toluene sulfonyl arginine methyl ester esterase activity) (p <0.01 for all) released into nasal secretions were significantly reduced after one week of pretreatment with theophylline. At the time of challenge, the serum concentrations of theophylline were between 8 and 22 μg/ml. It is speculated that the ability of theophylline to block the clinical response to antigen challenge and to decrease the release of mast cell mediators contributes to its clinical efficacy in the treatment of asthma.
AB - A nasal challenge model of allergic rhinitis was used to determine if pretreatment with oral theophylline reduces histamine release in vivo. Ten subjects were entered into a double-blind, cross-over trial. The results showed that both the physiologic response (sneezing) (p = 0.02) and the amount of mediators (histamine, kinins, toluene sulfonyl arginine methyl ester esterase activity) (p <0.01 for all) released into nasal secretions were significantly reduced after one week of pretreatment with theophylline. At the time of challenge, the serum concentrations of theophylline were between 8 and 22 μg/ml. It is speculated that the ability of theophylline to block the clinical response to antigen challenge and to decrease the release of mast cell mediators contributes to its clinical efficacy in the treatment of asthma.
UR - http://www.scopus.com/inward/record.url?scp=0022399985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022399985&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(85)90087-7
DO - 10.1016/0002-9343(85)90087-7
M3 - Article
C2 - 2417477
AN - SCOPUS:0022399985
SN - 0002-9343
VL - 79
SP - 43
EP - 47
JO - The American journal of medicine
JF - The American journal of medicine
IS - 6 SUPPL. 1
ER -